A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

Yao Tsung Tsai, Chen Hsien Liang, Jin Hsuan Yu, Kuan Chih Huang, Chia Hao Tung, Jia En Wu, Yi Ying Wu, Chih Hsien Chang, Tse Ming Hong, Yuh Ling Chen

Research output: Contribution to journalArticle

Abstract

Galectin-1 (Gal-1) is a pleiotropic homodimeric β-galactoside-binding protein with a single carbohydrate recognition domain. It has been implicated in several biological processes that are important during tumor progression. Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis. These observations all emphasized Gal-1 as a novel target for cancer immunotherapy. Here, we developed a novel Gal-1-targeting DNA aptamer (AP-74 M-545) and demonstrated its antitumor effect by restoring immune function. AP-74 M-545 binds to Gal-1 with high affinity. AP-74 M-545 targets tumors in murine tumor models but suppresses tumor growth only in immunocompetent C57BL/6 mice, not in immunocompromised non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Immunohistochemistry revealed increased CD4+ and CD8+ T cells in AP-74 M-545-treated tumor tissues. AP-74 M-545 suppresses T cell apoptosis by blocking the binding of Gal-1 to CD45, the main receptor and apoptosis mediator of Gal-1 on T cells. Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity. These results indicate that AP-74 M-545 may be a potential strategy for cancer immunotherapy.

Original languageEnglish
Pages (from-to)991-998
Number of pages8
JournalMolecular Therapy - Nucleic Acids
Volume18
DOIs
Publication statusPublished - 2019 Dec 6

Fingerprint

Galectin 1
Nucleotide Aptamers
Lung Neoplasms
T-Lymphocytes
Neoplasms
Apoptosis
Immunotherapy
Biological Phenomena
Galactosides
Severe Combined Immunodeficiency
Growth
Inbred C57BL Mouse
Cellular Immunity
Carrier Proteins
Immunohistochemistry
Carbohydrates

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Tsai, Yao Tsung ; Liang, Chen Hsien ; Yu, Jin Hsuan ; Huang, Kuan Chih ; Tung, Chia Hao ; Wu, Jia En ; Wu, Yi Ying ; Chang, Chih Hsien ; Hong, Tse Ming ; Chen, Yuh Ling. / A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer. In: Molecular Therapy - Nucleic Acids. 2019 ; Vol. 18. pp. 991-998.
@article{724717c65bf0498fbc09b45dbcb65241,
title = "A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer",
abstract = "Galectin-1 (Gal-1) is a pleiotropic homodimeric β-galactoside-binding protein with a single carbohydrate recognition domain. It has been implicated in several biological processes that are important during tumor progression. Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis. These observations all emphasized Gal-1 as a novel target for cancer immunotherapy. Here, we developed a novel Gal-1-targeting DNA aptamer (AP-74 M-545) and demonstrated its antitumor effect by restoring immune function. AP-74 M-545 binds to Gal-1 with high affinity. AP-74 M-545 targets tumors in murine tumor models but suppresses tumor growth only in immunocompetent C57BL/6 mice, not in immunocompromised non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Immunohistochemistry revealed increased CD4+ and CD8+ T cells in AP-74 M-545-treated tumor tissues. AP-74 M-545 suppresses T cell apoptosis by blocking the binding of Gal-1 to CD45, the main receptor and apoptosis mediator of Gal-1 on T cells. Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity. These results indicate that AP-74 M-545 may be a potential strategy for cancer immunotherapy.",
author = "Tsai, {Yao Tsung} and Liang, {Chen Hsien} and Yu, {Jin Hsuan} and Huang, {Kuan Chih} and Tung, {Chia Hao} and Wu, {Jia En} and Wu, {Yi Ying} and Chang, {Chih Hsien} and Hong, {Tse Ming} and Chen, {Yuh Ling}",
year = "2019",
month = "12",
day = "6",
doi = "10.1016/j.omtn.2019.10.029",
language = "English",
volume = "18",
pages = "991--998",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer. / Tsai, Yao Tsung; Liang, Chen Hsien; Yu, Jin Hsuan; Huang, Kuan Chih; Tung, Chia Hao; Wu, Jia En; Wu, Yi Ying; Chang, Chih Hsien; Hong, Tse Ming; Chen, Yuh Ling.

In: Molecular Therapy - Nucleic Acids, Vol. 18, 06.12.2019, p. 991-998.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer

AU - Tsai, Yao Tsung

AU - Liang, Chen Hsien

AU - Yu, Jin Hsuan

AU - Huang, Kuan Chih

AU - Tung, Chia Hao

AU - Wu, Jia En

AU - Wu, Yi Ying

AU - Chang, Chih Hsien

AU - Hong, Tse Ming

AU - Chen, Yuh Ling

PY - 2019/12/6

Y1 - 2019/12/6

N2 - Galectin-1 (Gal-1) is a pleiotropic homodimeric β-galactoside-binding protein with a single carbohydrate recognition domain. It has been implicated in several biological processes that are important during tumor progression. Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis. These observations all emphasized Gal-1 as a novel target for cancer immunotherapy. Here, we developed a novel Gal-1-targeting DNA aptamer (AP-74 M-545) and demonstrated its antitumor effect by restoring immune function. AP-74 M-545 binds to Gal-1 with high affinity. AP-74 M-545 targets tumors in murine tumor models but suppresses tumor growth only in immunocompetent C57BL/6 mice, not in immunocompromised non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Immunohistochemistry revealed increased CD4+ and CD8+ T cells in AP-74 M-545-treated tumor tissues. AP-74 M-545 suppresses T cell apoptosis by blocking the binding of Gal-1 to CD45, the main receptor and apoptosis mediator of Gal-1 on T cells. Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity. These results indicate that AP-74 M-545 may be a potential strategy for cancer immunotherapy.

AB - Galectin-1 (Gal-1) is a pleiotropic homodimeric β-galactoside-binding protein with a single carbohydrate recognition domain. It has been implicated in several biological processes that are important during tumor progression. Several lines of evidence have indicated that Gal-1 is involved in cancer immune escape and induces T cell apoptosis. These observations all emphasized Gal-1 as a novel target for cancer immunotherapy. Here, we developed a novel Gal-1-targeting DNA aptamer (AP-74 M-545) and demonstrated its antitumor effect by restoring immune function. AP-74 M-545 binds to Gal-1 with high affinity. AP-74 M-545 targets tumors in murine tumor models but suppresses tumor growth only in immunocompetent C57BL/6 mice, not in immunocompromised non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. Immunohistochemistry revealed increased CD4+ and CD8+ T cells in AP-74 M-545-treated tumor tissues. AP-74 M-545 suppresses T cell apoptosis by blocking the binding of Gal-1 to CD45, the main receptor and apoptosis mediator of Gal-1 on T cells. Collectively, our data suggest that the Gal-1 aptamer suppresses tumor growth by blocking the interaction between Gal-1 and CD45 to rescue T cells from apoptosis and restores T cell-mediated immunity. These results indicate that AP-74 M-545 may be a potential strategy for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85075459954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075459954&partnerID=8YFLogxK

U2 - 10.1016/j.omtn.2019.10.029

DO - 10.1016/j.omtn.2019.10.029

M3 - Article

AN - SCOPUS:85075459954

VL - 18

SP - 991

EP - 998

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -